Company: TVRD
Filing Date: 2025-02-14
Form Type: S-4/A
Source: 0001104659-25-013053
Chunk: 738

Company: Tvardi Therapeutics, Inc.
Filing Date: 2025-02-14
Form: S-4/A
Chunk 738
---
 2023, zero shares issued and outstanding at September 30, 2024 and December 31, 2023                                                                         | ​ | ​ | ​                 | ​ |        — | ​ | ​ | ​ | ​                | ​ |        — | ​ | ​ |
| Common stock; $0.001 par value; 16,666,667 shares and 8,333,333 shares authorized at September 30, 2024 and December 31, 2023, respectively, 4,750,553 shares and 4,540,059 shares issued and outstanding at September 30, 2024 and December 31, 2023,respectively | ​ | ​ | ​                 | ​ |        5 | ​ | ​ | ​ | ​                | ​ |        5 | ​ | ​ |
| Additional paid-in capital                                                                                                                                                                                                                                         | ​ | ​ | ​                 | ​ |  748,660 | ​ | ​ | ​ | ​                | ​ |  742,085 | ​ | ​ |
| Accumulated deficit                                                                                                                                                                                                                                                | ​ | ​ | ​                 | ​ | -747,933 | ​ | ​ | ​ | ​                | ​ | -684,745 | ​ | ​ |
| Accumulated other comprehensive loss                                                                                                                                                                                                                               | ​ | ​ | ​                 | ​ |      -25 | ​ | ​ | ​ | ​                | ​ |     -260 | ​ | ​ |
| Total stockholders’ equity                                                                                                                                                                                                                                         | ​ | ​ | ​                 | ​ |      707 | ​ | ​ | ​ | ​                | ​ |   57,085 | ​ | ​ |
| Total liabilities and stockholders’ equity                                                                                                                                                                                                                         | ​ | ​ | ​                 | $ |   51,329 | ​ | ​ | ​ | ​                | $ |  125,844 | ​ | ​ |

See Notes to Condensed Consolidated Financial Statements. F-2

TABLE OF CONTENTS

CARA THERAPEUTICS, INC. CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS
(amounts in thousands, excluding share and per share data)
(unaudited)

| ​                                                                                         
 ​                                                                                         
 Revenue:                                                                                  | ​ 
 ​ 
 ​ | ​ 
 ​ 
 ​ | Three Months Ended 
 September 30,2024  
 ​                  | ​ |         ​ | ​ | ​ 
 ​ | ​ 
 ​ | September 30,